Informazioni generali
  • Categoria della malattia Infezioni e infestazioni , Malattie delle vie respiratorie (non cancro) (BASEC)
  • Stato di reclutamento reclutamento in corso (BASEC/ICTRP)
  • Luogo dello studio
    Aarau, Basilea, Bellinzona, Berna, Chur, Friburgo, Ginevra, Losanna, Luzern, San Gallo, Winterthur, Zurigo
    (BASEC)
  • Responsabile dello studio PD Dr. Dr. med. Patrick M. Meyer Sauteur patrick.meyersauteur@kispi.uzh.ch (BASEC)
  • Fonte dati BASEC: Importato da 24.03.2025 ICTRP: N/A
  • Ultimo aggiornamento 24.03.2025 15:10
HumRes65033 | SNCTP000005900 | BASEC2023-01295

A randomized controlled study on the use of antibiotics in children with pneumonia caused by mycoplasma

  • Categoria della malattia Infezioni e infestazioni , Malattie delle vie respiratorie (non cancro) (BASEC)
  • Stato di reclutamento reclutamento in corso (BASEC/ICTRP)
  • Luogo dello studio
    Aarau, Basilea, Bellinzona, Berna, Chur, Friburgo, Ginevra, Losanna, Luzern, San Gallo, Winterthur, Zurigo
    (BASEC)
  • Responsabile dello studio PD Dr. Dr. med. Patrick M. Meyer Sauteur patrick.meyersauteur@kispi.uzh.ch (BASEC)
  • Fonte dati BASEC: Importato da 24.03.2025 ICTRP: N/A
  • Ultimo aggiornamento 24.03.2025 15:10

Descrizione riassuntiva dello studio

In the MYTHIC Study, we want to find out whether the treatment of pneumonia caused by mycoplasma with antibiotics is really necessary. Pneumonia is caused by bacteria, viruses, or fungi. Antibiotic therapy is only effective against bacteria. Each antibiotic also works only against certain types of bacteria. Mycoplasmas (Mycoplasma pneumoniae) are one of the most common bacterial causes of pneumonia in children. The recommended antibiotics against mycoplasmas are macrolides, which are the second most commonly used antibiotics in children after penicillin antibiotics. However, the effectiveness of macrolides in children with mycoplasma pneumonia is unclear. The excessive use of macrolides has led to a global development of bacterial resistance to these antibiotics. Therefore, it is important to use antibiotics only when absolutely necessary. Based on clear evidence from previous studies, we assume that children receiving macrolides will take the same time to recover from mycoplasma infection as children receiving a placebo. The children will be closely monitored during the study, so participation in the study poses no risk to the children.

(BASEC)

Intervento studiato

In this study, participants will be randomly assigned to two groups: Group 1 (experimental group) will receive a macrolide antibiotic and Group 2 (control group) will receive a placebo (medication without active ingredient). Neither the participants nor the investigators will know who has been assigned to which group. The idea is to minimize the influence on the results. Through these measures, we can objectively assess whether the placebo is not worse than the antibiotic. The study lasts 28 days and includes 2 additional examinations as well as 3 telephone check-ups.

(BASEC)

Malattie studiate

A bacterial pneumonia is usually treated with antibiotics. Many antibiotics are no longer effective due to the development of bacterial resistance. In this study, we investigate whether the treatment of pneumonia caused by mycoplasmas with antibiotics is really necessary.

(BASEC)

Criteri di partecipazione
- Children and adolescents aged 3-17 years presenting to the emergency department with pneumonia - Clinical diagnosis of pneumonia AND fever >38°C AND tachypnea (respiratory rate above age-specific reference values) - Positive screening test for mycoplasma infection - Written informed consent (BASEC)

Criteri di esclusione
- Known intolerance to azithromycin - Underlying comorbidities: cystic fibrosis or other chronic lung diseases (excluding asthma), primary or secondary immunodeficiency, cardiovascular disease, or severe cerebral palsy or myasthenia gravis - History of recurrent pneumonia (two or more episodes) or severe pneumonia - Antibiotic treatment for mycoplasmas within the last 7 days - Transfer to intensive care directly from the emergency department - Inability to take oral medications - It is unlikely that parents will attend follow-up visits as part of the study and reliably complete questionnaires, e.g., due to language barriers or because they live far from the study site (BASEC)

Luogo dello studio

Aarau, Basilea, Bellinzona, Berna, Chur, Friburgo, Ginevra, Losanna, Luzern, San Gallo, Winterthur, Zurigo

(BASEC)

non disponibile

Sponsor

Christoph Berger - University Children's Hospital Zurich

(BASEC)

Contatto per ulteriori informazioni sullo studio

Persona di contatto in Svizzera

PD Dr. Dr. med. Patrick M. Meyer Sauteur

+41 44 266 78 96

patrick.meyersauteur@kispi.uzh.ch

University Children's Hospital Zurich

(BASEC)

Informazioni scientifiche

non disponibile

Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)

Commissione etica Zurigo

(BASEC)

Data di approvazione del comitato etico

14.05.2024

(BASEC)


ID di studio ICTRP
non disponibile

Titolo ufficiale (approvato dal comitato etico)
A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia - MYTHIC Study (BASEC)

Titolo accademico
non disponibile

Titolo pubblico
non disponibile

Malattie studiate
non disponibile

Intervento studiato
non disponibile

Tipo di studio
non disponibile

Disegno dello studio
non disponibile

Criteri di inclusione/esclusione
non disponibile

non disponibile

Endpoint primari e secondari
non disponibile

non disponibile

Data di registrazione
non disponibile

Inclusione del primo partecipante
non disponibile

Sponsor secondari
non disponibile

Contatti aggiuntivi
non disponibile

ID secondari
non disponibile

Risultati-Dati individuali dei partecipanti
non disponibile

Ulteriori informazioni sullo studio
non disponibile


Risultati dello studio

Riepilogo dei risultati

non disponibile

Link ai risultati nel registro primario

non disponibile